4572.T
Carna Biosciences,Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 409.00
+0.74%Year over year
Reported trailing growth
- Revenue
- -9.0%
- EBITDA
- —
- EBIT
- +0.1%
- EPS
- +8.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +24.7%
- EBITDA
- —
- EPS
- +1.0%
Three-year CAGR
- Revenue
- -25.2%
- EBITDA
- —
- EBIT
- +0.1%
- Net income
- +0.3%
- EPS
- +6.6%
- Free cash flow
- -56.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026